— InnovaRadi Therapeutics Co., Ltd. Enters into Strategic Collaboration with Sichuan University to Advance the R&D of Innovative Targeted α-Emitting Radiotherapeutics Based on ²¹¹At

2025-12-31

Recently, InnovaRadi Therapeutics Co., Ltd. (hereinafter referred to as “InnovaRadi”) officially announced the establishment of a major strategic collaboration with West China Hospital of Sichuan University & Institute of Nuclear Science and Technology, Sichuan University. Leveraging their respective leading strengths in clinical medicine, basic research, radiochemistry, and drug development, the parties will jointly focus on the unmet needs of precision oncology and build a collaborative innovation system spanning basic research, clinical validation, and industrial translation. They are committed to advancing the research, development, and clinical translation of innovative targeted alpha-emitting radiotherapeutics based on astatine-211 (²¹¹At). This strategic partnership marks a critical milestone for InnovaRadi in deepening the integration of industry, academia, research, and clinical medicine within the fields of nuclear medicine, precision diagnostics and therapeutics.